Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17006543
Salcedo A, Mayor F, Penela P (2006) Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. EMBO J 25, 4752-62 17006543
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

K19-ub - GRK2 (human)
Modsite: SyLMAMEkSkATPAA SwissProt Entrez-Gene
Orthologous residues
GRK2 (human): K19‑ub, GRK2 (mouse): K19‑ub, GRK2 (rat): K19‑ub, GRK2 (cow): K19‑ub
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ARRB2 (human) increase
isoproterenol increase
siRNA decrease siRNA for Mdm2 decreases ubiquitination
Downstream Regulation
Effect of modification (function):  protein degradation

K21-ub - GRK2 (human)
Modsite: LMAMEkSkATPAARA SwissProt Entrez-Gene
Orthologous residues
GRK2 (human): K21‑ub, GRK2 (mouse): K21‑ub, GRK2 (rat): K21‑ub, GRK2 (cow): K21‑ub
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ARRB2 (human) increase
isoproterenol increase
siRNA decrease siRNA for Mdm2 decreases ubiquitination
Downstream Regulation
Effect of modification (function):  protein degradation

K30-ub - GRK2 (human)
Modsite: TPAARAskkILLPEP SwissProt Entrez-Gene
Orthologous residues
GRK2 (human): K30‑ub, GRK2 (mouse): K30‑ub, GRK2 (rat): K30‑ub, GRK2 (cow): K30‑ub
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ARRB2 (human) increase
isoproterenol increase
siRNA decrease siRNA for Mdm2 decreases ubiquitination
Downstream Regulation
Effect of modification (function):  protein degradation

K31-ub - GRK2 (human)
Modsite: PAARAskkILLPEPS SwissProt Entrez-Gene
Orthologous residues
GRK2 (human): K31‑ub, GRK2 (mouse): K31‑ub, GRK2 (rat): K31‑ub, GRK2 (cow): K31‑ub
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ARRB2 (human) increase
isoproterenol increase
siRNA decrease siRNA for Mdm2 decreases ubiquitination
Downstream Regulation
Effect of modification (function):  protein degradation